J' Michael Hasenkam - PowerPoint PPT Presentation

1 / 37
About This Presentation
Title:

J' Michael Hasenkam

Description:

J' Michael Hasenkam – PowerPoint PPT presentation

Number of Views:122
Avg rating:3.0/5.0
Slides: 38
Provided by: annettes3
Category:
Tags: a4a | hasenkam | michael

less

Transcript and Presenter's Notes

Title: J' Michael Hasenkam


1
?
  • How Computer aided Dosing would help with Patient
    Self Management ?

2
(No Transcript)
3
(No Transcript)
4
(No Transcript)
5
MANAGEMENT CONCEPTS
  • General Physician
  • Cardiologist/Hematologist
  • Hospital Outpatient Clinic
  • Thrombosis Service
  • Computer Dosaging
  • Patient Self Management

6
CONVENTIONAL MANAGEMENT
  • Go to Lab
  • Analysis of blood specimen
  • Result to doctor
  • Perscription of Warfarin dosage
  • Decide next visit
  • Information to patient Comply with schedule
  • ENTIRE LIFE!!

7
THE MODERN PATIENT
  • Knowledgeable about own therapy
  • Influence
  • Avoid role as a patient
  • Travel
  • Manage studies/professional work

8
SELF MANAGEMENT OF OAT
  • Less dependence of health care system
  • Better awareness of therapy
  • Improved compliance
  • Co-responsibility for therapy
  • Better management of OAT

9
(No Transcript)
10
(No Transcript)
11
(No Transcript)
12
(No Transcript)
13
(No Transcript)
14
(No Transcript)
15
CONCERNS
  • Home coagulometer reliable?
  • Patients capable to analyze blood specimens?
  • Can patients handle dosage adjustments?
  • Who is responsible for patient complications?

16
(No Transcript)
17

18
(No Transcript)
19
Week no. Hospital INR CoaguChek
INR Anticipated Skills Interview Self
Control Lab Check
Weeks no Hospital INR CoaguChek
INR Anticipated Skills Interview Self
Control Lab Check
20
COMPLICATION RATES
  • BLEEDINGS
  • Large Studies
  • (AFASAK, BAATAF, SPINAF, SPAF (I,II,III)
  • 1 3
  • Everyday (Steffensen et al.)
  • 6 (1 fatal)
  • THROMBO-EMBOLISM
  • Large Studies
  • 2 4
  • Everyday
  • Reliable figures?

21
CLINICAL END-POINTS
Serious Bleedings 14 (7 epistaxis 2
traumatic 5 GI/UG))
Expected (Steffensen) 33
Thrombo-embolic events 5 (2 DVT 1 ocular 2
fatal)
Expected (4) 22
370 patients 556 pt-years
22
TIME IN THERAPEUTIC RANGE
23
REASONS FOR SUPERIORITY OF SELF MANAGEMENT
  • Frequent testing
  • Patient training
  • Dosage adjustment according to other factors than
    INR
  • Patient selection (only compliant patients
    volonteer)
  • Coagulometer ?

24
Where does Computer Dosaging Fit in Here?
25
CONTINUUM OF PATIENT CHARACTERISTICS
  • Entirely self managing
  • Self testing - dosaging with limits
  • Self testing dosaging by health care provider
  • Entirely dependent on health care provider

26
CONTINUUM OF HEALTH CARE PROVIDERS
  • Self managing patients superior to computer
  • Specialists equal to/better than Computer
  • GP/Young Doctors inferior to Computer
  • Untrained Patients inferior to Doctor and Computer

27
PLACE FOR COMPUTER DOSAGING
  • Outpatient clinic
  • General Physician
  • Self testing patients
  • Support in self managing by proxy
  • Web based decision support
  • Software at the patients home
  • Web/e-mail report from patient to clinic

28
PERSPECTIVES
  • Computer dosaging central/near patient
  • Improve quality of life
  • Educate patients
  • Improve compliance
  • Reduce complications

29
LETS INDIVIDUALIZE !
?
?
  • Self management
  • Thrombosis Service
  • Computerized Decision support
  • Centralized
  • Near Patient

30
ISMAAInternational Self Management Association
for Anticoagulation
  • Improve quality of OAT
  • Reduce complications
  • Promote self managed OAT
  • Enhance patient involvement
  • Improve Quality of Life for patients
  • Cost-Effectiveness of care

http//www.ismaa-int.org
31
MEANS
  • Scientific Meetings
  • Guidelines
  • Courses for health care providers
  • Interaction with other societies
  • Interaction with patients (collaborators not
    traditional patients)
  • Industrial collaborators

32
Self managed
33
Guidelines
  • Patient Education
  • Coagulometer Performance
  • Demands for Training center
  • Follow-up procedure
  • Consultation for patients

34
AGE
N 370
Years
35
OAT DRUGS
36
RELIABILITY
PRECISION Analytical CV 5 6 (short
term) 9 10 (long term) 2 3 (short
term) 7 9 (long term) ACCURACY Diff
lab. and Coaguchek CV 8 10 (varies over
time) Corresponds to diff. between laboratories
in DK

COAGUCHEK

LABORATORY
37
INDICATIONS FOR OAT
Misc.
Mechanical Heart Valve
Coagulopathy
Atrial Fibrillation
Write a Comment
User Comments (0)
About PowerShow.com